In a significant development for Enliven Therapeutics (ELVN, Financial), Goldman Sachs has initiated coverage on the stock with a "Buy" rating. This move by the global investment banking giant marks a critical endorsement for the biotechnology company.
The coverage initiation, announced on June 16, 2025, by Salveen Richter, a prominent analyst at Goldman Sachs, comes with a price target of USD 37.00. The rating highlights the potential upside for ELVN as it navigates the competitive field of therapeutic innovations.
This new "Buy" rating by Goldman Sachs sets the stage for possible increased investor interest in ELVN. The price target of USD 37.00 underscores the confidence in the company's future prospects and growth trajectory.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Enliven Therapeutics Inc (ELVN, Financial) is $40.13 with a high estimate of $52.00 and a low estimate of $33.00. The average target implies an upside of 73.10% from the current price of $23.18. More detailed estimate data can be found on the Enliven Therapeutics Inc (ELVN) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Enliven Therapeutics Inc's (ELVN, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
